when was the first glp 1 agonist approved GLP-1 Receptor Market Growth Analysis Timeline of SGLT2i and GLP-1RA

GHK-Cu, the tripeptide glycyl-L-histidyl-L-lysine bound to copper, demonstrates activity at concentrations that would seem impossibly small to anyone familiar with standard peptide dosing

Targeting each step of glutamine metabolism has shown promising results in cancer treatment, prompting the discovery of druggable targets and the development of anticancer drug candidates 3

Studies have demonstrated that PNS also exhibits powerful protective effects against DKD and AKI (Li et al., 2021c

Additional Phase 3 trials are still underway, including TRIUMPH-2 (evaluating retatrutide in adults with obesity and type 2 diabetes) and TRIUMPH-3 (evaluating cardiovascular outcomes), with results expected later in 2026